哮喘联盟

   摘要
   背景：丙酸氟替卡松和福莫特罗富马酸盐混合装入到吸入器中（氟替卡松/福莫特罗; flutiform ®）用于哮喘的维持治疗。该汇总分析对比了氟替卡松/福莫特罗和氟替卡松对于曾接受吸入糖皮质激素治疗患者的疗效。
   方法：数据源于五项随机研究。在这些随机研究中，哮喘患者(年龄≧12岁)使用氟替卡松/福莫特罗联合治疗（100/10, 250/10 或 500/20μg b.i.d.；n = 528 通过吸入器吸入）或单独使用氟替卡松（100, 250 or 500 μg b.i.d.; n = 527）治疗8周或12周。
   结果： 相对于单独使用氟替卡松，氟替卡松/福莫特罗联合使用更显著地提高从给药前基线至给药后2小时即研究结束时的平均早晨1秒用力呼气量（FEV1）（最小二乘均数[LSM]治疗差异：0.146L; p <0.001），和从基线值到研究结束的给药前FEV1（LSM治疗差异：0.048 L，p =0.043）。与氟替卡松相比，氟替卡松/福莫特罗联合使用更大地提高从基线到研究结束的哮喘控制天数（无症状、无急救药物的使用和无因哮喘引起的睡眠障碍）的百分比（LSM治疗差异：8.6％; p <0.001），并与较低的年度急性发作比率（比率：0.71; p =0.014）相关。
   结论：总而言之，氟替卡松/福莫特罗联合使用能显著改善肺功能和控制哮喘，且相对于单独使用氟替卡松，哮喘急性发作的发生率更低。
 

（苏楠 审校）
Respir Med. 2014 Dec 3. pii: S0954-6111(14)00410-7. doi: 10.1016/j.rmed.2014.10.019. [Epub ahead of print]


 

Efficacy of fluticasone propionate/formoterol fumarate in the treatment of asthma: A pooled analysis.
 

Papi A1, Price D2, Sastre J3, Kaiser K4, Lomax M5, McIver T6, Dissanayake S7.
 

Abstract
BACKGROUND: Fluticasone propionate and formoterol fumarate have been combined in a single inhaler (fluticasone/formoterol; flutiform®) for the maintenance treatment of asthma. This pooled analysis assessed the efficacy of fluticasone/formoterol versus fluticasone in patients who previously received inhaled corticosteroids.
METHODS: Data were pooled from five randomised studies in patients with asthma (aged ≥12 years) treated for 8 or 12 weeks with fluticasone/formoterol (100/10, 250/10 or 500/20 μg b.i.d.; n = 528 delivered via pMDI) or fluticasone alone (100, 250 or 500 μg b.i.d.; n = 527).
RESULTS:Fluticasone/formoterol provided significantly greater increases than fluticasone alone in mean morning forced expiratory volume in 1 second (FEV1) from pre-dose at baseline to 2 hours post-dose at study end (least-squares mean [LSM] treatment difference: 0.146L; p < 0.001) and in pre-dose FEV1 from baseline to study end (LSM treatment difference: 0.048 L; p = 0.043). Compared with fluticasone, fluticasone/formoterol provided greater increases in the percentage of asthma control days (no symptoms, no rescue medication use and no sleep disturbance due to asthma) from baseline to study end (LSM treatment difference: 8.6%; p < 0.001), and was associated with a lower annualised rate of exacerbations (rate ratio: 0.71; p = 0.014).
CONCLUSIONS: In summary, fluticasone/formoterol provides clinically significant improvements in lung function and asthma control measures, with a lower incidence of exacerbations than fluticasone alone.
 

Respir Med. 2014 Dec 3. pii: S0954-6111(14)00410-7. doi: 10.1016/j.rmed.2014.10.019. [Epub ahead of print]